-- 2026年4月27日，全球首席商業化長安東尼·曼奇尼(Anthony Mancini)出售了Revolution Medicines (RVMD)的3,120股股票，套現413,129美元。根據向美國證券交易委員會(SEC)提交的4號表格文件，曼奇尼目前持有該公司54,400股普通股，其中54,400股為直接持有。 SEC文件連結： https://www.sec.gov/Archives/edgar/data/1628171/000161071726000158/xslF345X05/form4.xml
Related Articles
Asia
Mineral Resources Secures $1.3 Billion in Senior Notes Offering
Mineral Resources (ASX:MIN) completed the issue of $650 million in 6% senior unsecured notes due 2032 and a further $650 million in 6.25% notes due 2034, using the proceeds to refinance existing debt and strengthen its overall financial position, according to a Thursday filing with the Australian bourse.The proceeds and cash on hand will refinance $625 million of 2027 notes, repay $300 million of iron ore prepayments, partially redeem $350 million of 2028 notes, and fund the remaining $750 million of 2028 notes expected to be repaid after completing a lithium partnership with POSCO Holdings, per the filing.The company will have no material debt maturities until 2030 once these steps are completed and expects to reduce annual finance costs by around $150 million, improving financial flexibility for future capital allocation, the filing added.
$ASX:MIN
Research
Research Alert: Amrize Q1: Materials Growth Offset By Envelope Decline, Guidance Intact
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AMRZ reported mixed Q1 2026 results, with revenue growing 4.7% to $2.178B, though adjusted EBITDA fell 10.3% to $192M and margins compressed 150 bps to 8.8%. Building Materials segment strength (+12.9% revenue, +230 bps margin expansion) was offset by Building Envelope weakness (-9.8% revenue, -500 bps margin contraction). The company announced plans to begin its $1B share repurchase program and paid its first quarterly dividend of $0.11 per share. Management reaffirmed full-year guidance for revenue of $12.29B-$12.52B (up 4%-6%) and adjusted EBITDA of $3.25B-$3.34B (up 8%-11%). Consolidated profitability was pressured by elevated corporate costs of $56M following the Holcim separation, up from $30M prior year, though segment-level EBITDA excluding corporate costs increased 1.6%. Net leverage remained at 1.7x, with negative FCF of $1.163B reflecting typical seasonal patterns where cash generation concentrates in the second half.
$AMRZ
Asia
ASX Appoints Interim CEO
ASX (ASX:ASX) appointed Darren Yip, group executive of markets and listings, as interim chief executive, succeeding Helen Lofthouse, effective May 29, according to a Thursday filing with the Australian bourse.Yip will lead the company on an interim basis while the board continues its search for a permanent CEO, the filing added.
$ASX:ASX